Nan Fung Life Sciences
25
61M
15
3.57
2
0.40
6
- Stages of investment
- Areas of investment
Summary
The high activity for fund was in 2019. The higher amount of exits for fund were in 2019. The real fund results show that this VC is 10 percentage points less often commits exit comparing to other companies. Opposing the other organizations, this Nan Fung Life Sciences works on 19 percentage points less the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. Deals in the range of 50 - 100 millions dollars are the general things for fund.
Among the most popular portfolio startups of the fund, we may highlight Harmony Biosciences, Omniome, Bolt Biotherapeutics. We can highlight the next thriving fund investment areas, such as Therapeutics, Pharmaceutical. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Nan Fung Life Sciences, startups are often financed by New Enterprise Associates, Novartis Venture Fund, Maveron. The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, HBM Healthcare Investments AG, Vivo Capital. In the next rounds fund is usually obtained by Schwab Institutional, Pivotal bioVenture Partners China, Panacea Venture.
Investments analytics
Analytics
- Total investments
- 25
- Lead investments
- 2
- Exits
- 6
- Rounds per year
- 3.57
- Follow on index
- 0.40
- Investments by industry
- Biotechnology (19)
- Health Care (18)
- Pharmaceutical (10)
- Life Science (9)
- Medical Device (7) Show 7 more
- Investments by region
-
- United States (20)
- China (3)
- Iceland (2)
- Peak activity year
- 2021
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Group Appearance index
- 0.88
- Avg. company exit year
- 22
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| DermBiont | 21 Dec 2021 | Biotechnology, Health Care, Medical, Therapeutics | Early Stage Venture | 28M | United States, Massachusetts, Boston |
| OncXerna Therapeutics | 10 Jun 2019 | Biotechnology, Medical Device, Pharmaceutical, Biopharma | Early Stage Venture | 80M | United States, Massachusetts, Waltham |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.